Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)

<p>The purpose of this notice of funding opportunity (NOFO) is to support research to elucidate how HIV-induced immunometabolic alterations, in a host suppressed on combination antiretroviral therapy (cART-suppressed), impact the immune response and increase risk for poor outcomes due to a second, potentially long-term, infection such as Mycobacterium tuberculosis (Mtb) or Hepatitis B Virus (HBV). This NOFO aims to support research to define how HIV-driven alterations to immunometabolism affect immune cell regulation, cell-cell interactions, response to treatment, and, ultimately, Tuberculosis (TB) and HBV disease progression.</p>